Mr. Meyers has over thirty years of commercial leadership experience in the biopharmaceutical industry and worked at Gilead from 1996 until December 2021, most recently serving as a Senior Advisor. During his time at Gilead, he served as Executive Vice President of Worldwide Commercial Operations, where he was responsible for global commercial activities, including pricing and market access in North America, Europe, Middle East, Australia, and Japan. Mr. Meyers led some of the most important and successful product launches in the history of the biopharmaceutical industry, most notably in the therapeutic areas of HIV and HCV. Over the course of more than two decades at Gilead, Mr. Meyers was part of a small group of executives who led the transition of the company from an innovative start-up to a profitable and successful global biopharmaceutical company that delivered more than $28 billion in revenue in 2024 and more importantly, has changed the course of disease in HIV and HCV. Prior to Gilead, Mr. Meyers held positions of increasing responsibility with AstraZeneca. Most recently, Mr. Meyers served as President and Chief Executive Officer of IntraBio Ltd. from 2020 to 2024. Mr. Meyers currently serves on the Board of Directors of two public companies, Sangamo Therapeutics, Inc. and CytomX Therapeutics, Inc. He also remains a Senior Advisor at BCG to several major biopharmaceutical companies. Mr. Meyers holds a B.S. in Economics from Boston College.